Inventiva (NASDAQ:IVA) Price Target Cut to $20.00

Inventiva (NASDAQ:IVA) had its target price lowered by research analysts at Stifel Nicolaus from $25.00 to $20.00 in a report released on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Inventiva Stock Down 15.3 %

Shares of IVA traded down $0.33 during trading hours on Thursday, hitting $1.83. 41,565 shares of the stock were exchanged, compared to its average volume of 20,900. The stock’s 50-day moving average price is $2.28 and its two-hundred day moving average price is $2.99. Inventiva has a 12-month low of $1.53 and a 12-month high of $4.75.

Institutional Investors Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC acquired a new position in shares of Inventiva S.A. (NASDAQ:IVA) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.